top of page

News Center

Check out the latest news from Ocelot Bio.

October 24, 2022

Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting


-- Poster session to feature first presentation of data from completed Phase 1 trial of OCE-205

-- Study findings support and inform protocol for OCE-205 Phase 2 clinical program underway


SAN DIEGO, CALIF. – (October 24, 2022) – Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), will present data from the completed Phase 1 healthy volunteer clinical trial for its lead candidate, OCE-205, at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, taking place November 4-8, 2022, in Washington, DC.

“With its unique profile as a mixed agonist-antagonist therapeutic peptide and a highly differentiated mechanism of action, OCE-205 offers promise as a novel therapeutic option uniquely designed to address the long-standing needs in the clinical management of complications associated with end-stage liver disease,” said Stan Bukofzer, M.D., chief scientific & medical officer at Ocelot Bio. “We recognize that physicians are eager for new treatment options that improve the management of, and patient outcomes associated with common complications of decompensated cirrhosis, such as hepatorenal syndrome and ascites, particularly given established limitations of currently available treatment approaches. We look forward to this opportunity to present, for the first time, data from our Phase 1 trial that underscores the potential of OCE-205 to address these limitations.”

Ocelot Bio’s poster at The Liver Meeting is titled “OCE-205, a Novel, Selective Vasopressin (V1a) Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study” (#3622) and will be presented by Geoff Harris, Ph.D., founder of Ocelot Bio, on Sunday, November 6, 2022, at 1:00 p.m. Additionally, the poster has been selected for inclusion in the Portal Hypertension Special Interest Group (SIG) poster debrief on Sunday, November 6, at 8:00 a.m. SIG poster debriefs feature four selected posters within a specialty and are designed to highlight the latest science and encourage networking among professionals from within that specialty. The full poster presentation will also be made available to registered meeting attendees via The Liver Meeting Digital Experience™ within 72 hours of presentation, and the poster will be available online at Ocelot Bio’s website. 

OCE-205 is a mixed agonist-antagonist therapeutic peptide that has a mechanism of action designed to selectively target consequences of the systemic hemodynamic complications associated with decompensated liver cirrhosis, or ESLD. Ocelot Bio is currently enrolling patients in its Phase 2 clinical trial evaluating OCE-205 for the treatment of hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and rapidly progressive consequence of ESLD (NCT05309200). The trial is a multi-center, randomized, placebo-controlled, double-blind, adaptive dose-ranging study that aims to assess the safety and efficacy of OCE-205 in adults diagnosed with cirrhosis with ascites who have developed HRS-AKI. The company has received Orphan Drug Designation for OCE-205 in the treatment of hepatorenal syndrome from the U.S. Food and Drug Administration.


About Ocelot Bio

Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD). The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital.


Media Contact

Christy Curran

Sam Brown, Inc.

(615) 414-8668

Patients can’t wait and neither will we.

Our passion for improving the lives of people with severe complications of liver disease is the foundation of our company.

bottom of page